Sanofi: acquires Origimm Biotechnology
(CercleFinance.com) - Sanofi today announced that it has signed an agreement to acquire Origimm Biotechnology, an Austrian company specialising in the R&D of antigens aimed at modulating the immune response in skin diseases associated with the cutaneous microbiota.
Thanks to this acquisition, the French healthcare group continues to execute its global Play to Win strategy, seeking growth opportunities and developing a portfolio of leading vaccine candidates.
In particular, this transaction will enable it to add ORI-001, a therapeutic vaccine candidate for acne vulgaris, which affects millions of people worldwide, to its portfolio of early-stage projects.
Copyright (c) 2021 CercleFinance.com. All rights reserved.